Teva Pharmaceutical Industries (TEVA) Asset Writedowns and Impairment: 2009-2024
Historic Asset Writedowns and Impairment for Teva Pharmaceutical Industries (TEVA) over the last 7 years, with Mar 2024 value amounting to $679.0 million.
- Teva Pharmaceutical Industries' Asset Writedowns and Impairment rose 259.26% to $679.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $1.6 billion, marking a year-over-year decrease of 36.53%. This contributed to the annual value of $1.1 billion for FY2023, which is 55.95% down from last year.
- As of Q1 2024, Teva Pharmaceutical Industries' Asset Writedowns and Impairment stood at $679.0 million, which was up 898.53% from $68.0 million recorded in Q4 2023.
- In the past 5 years, Teva Pharmaceutical Industries' Asset Writedowns and Impairment registered a high of $5.2 billion during Q3 2020, and its lowest value of $28.0 million during Q3 2022.
- Over the past 3 years, Teva Pharmaceutical Industries' median Asset Writedowns and Impairment value was $189.0 million (recorded in 2023), while the average stood at $467.3 million.
- In the last 5 years, Teva Pharmaceutical Industries' Asset Writedowns and Impairment spiked by 2,433.66% in 2020 and then plummeted by 99.10% in 2021.
- Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' Asset Writedowns and Impairment stood at $232.0 million in 2020, then fell by 21.12% to $183.0 million in 2021, then skyrocketed by 689.62% to $1.4 billion in 2022, then slumped by 95.29% to $68.0 million in 2023, then soared by 259.26% to $679.0 million in 2024.
- Its last three reported values are $679.0 million in Q1 2024, $68.0 million for Q4 2023, and $48.0 million during Q3 2023.